The Cellular Goods share price slips. Is this Beckham-backed cannabis stock a buy?

Cannabis stock Cellular Goods (LSE:CBX) launched via IPO last week but its shares have pulled back. Is this CBD health company a good investment?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Cellular Goods (LSE:CBX) launched on the London Stock Exchange last week after a very successful initial public offering (IPO). It’s an early stage cannabis company potentially arriving at an opportune time. Fellow cannabis stocks Kanabo and MXC Pharmaceuticals also launched in London in recent weeks to an explosive response.

Cellular Goods is a public facing cannabinoid company backed by David Beckham. It launched on Friday at 19p a share, but has since fallen to 12p. In its pre-market placing it was oversubscribed by 13 times. I think this is due to rising enthusiasm and excitement in the growing cannabis arena, along with Beckham’s influence.

A £1bn industry

The cannabinoid field is massive and growing rapidly. Cannabidiol (CBD) is one type of cannabinoid gaining popularity as it’s used to treat a multitude of health conditions. This includes inflammation and pain relief as well as mental health issues and sleep. While we derive some CBD products directly from the cannabis plant, others are synthetically created in a lab. Cellular Goods intends to make synthetic CBD products focusing on skincare and athletic recovery.

The Centre for Medicinal Cannabis has found that 1,300,000 British consumers are already using CBD products. It also estimates that the market, which is showing double-digit growth, could be worth almost £1bn a year by 2025.

However, the company hasn’t yet produced any products, so its investors are purely pinning their hopes on the potential for success. It also doesn’t plan to announce any products before September, which is a long time for shareholders to patiently wait.

Powder of Cannabis (Drugs), Analysis of Cannabis in laboratory.

Synthetic cannabinoids

The company claims that making the products in a lab affords a level of scientific precision that avoids pesticides and a more sustainable product. But on a cellular level, they’re bio-identical to plant-based cannabinoids.

I think the future success of this company will come down to the quality of its products and the success of its marketing campaign. Beckham owns 5% of the company through his investment company, DB Ventures. His athletic background and high profile might help propel the brand if he’s involved in the marketing, but I would imagine that’s unlikely.

Should I buy shares in Cellular Goods?

At the moment, I’ve no plans to invest in Cellular Goods. I think it’s too early to gauge how the company will progress. And I think there’s already quite a lot of competition out there. Even FTSE 100 heavyweight British American Tobacco is making inroads into the CBD market.

It’s well known that the health, beauty, and sports supplements sector is thoroughly saturated. I understand the appeal of CBD products and many people advocate they’re a great help for painful conditions such as arthritis. Therefore, I think it certainly has a chance at success. But it seems quite a risky investment at this stage. And I think there are plenty of other exciting stocks I’d prefer to add to my portfolio.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Kirsteen has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

The Rolls-Royce share price is down 10% since a 52-week high. Is this a buying dip?

H1 results from Rolls-Royce are just around the corner, but what might they mean for the share price? I expect…

Read more »

Investing Articles

5.5% dividend yield! Is this FTSE 100 stock a great buy for dividend growth?

A falling share price has supercharged the dividend yield on this FTSE 100 share. Here's why it could be a…

Read more »

Investing Articles

UK shares: a once-in-a-decade chance to bag sky-high passive income

The FTSE 250 is offering up incredible passive income opportunities right now. Our writer takes a look at one stock…

Read more »

Investing Articles

2 dirt cheap FTSE 100 and FTSE 250 growth shares to consider!

Looking for great growth and value shares right now? These FTSE 100 and FTSE 250 shares could offer the best…

Read more »

Investing Articles

No savings? I’d use the Warren Buffett method to target big passive income

This Fool looks at a couple of key elements of Warren Buffett's investing philosophy that he thinks can help him…

Read more »

Investing Articles

This FTSE 100 hidden gem is quietly taking things to the next level

After making it to the FTSE 100 index last year, Howden Joinery Group looks to be setting its sights on…

Read more »

Investing Articles

A £20k Stocks and Shares ISA put into a FTSE 250 tracker 10 years ago could be worth this much now

The idea of a Stocks and Shares ISA can scare a lot of people away. But here's a way to…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

What next for the Lloyds share price, after a 25% climb in 2024?

First-half results didn't do much to help the Lloyds Bank share price. What might the rest of the year and…

Read more »